Nemucore Medical Innovations is here to bring you the future of cancer care. Theyâre developing a new type of targeted therapy that ââŚrelies on knowledge from an RNA-based diagnostic instead of more traditional DNA-based diagnostics to determine if a patient with cancer is a candidate for our targeted therapy.â They believe that this type of diagnostic will help unlock targeted therapies for the 70% of cancer patients who do not have âdruggableâ genetic mutations in their DNA. So far, Nemucore has raised $7M from foundation grants and the National Cancer Institute; they have over 57 investors; and leading experts at Memorial Sloan Kettering and Moffitt Cancer Centers are set to perform their clinical trial. Plus, their leadership team has over 100 years of biopharmaceutical experience. The bottom line? Nemucore wants, with this campaign, to âcure AML together and open a new future of cancer care.â Source
No articles found.
As a leading provider of innovative technologies for the treatment of Atrial Fibri...
As a leading provider of innovative technologie...
Five Prime Therapeutics, Inc. discovers and develops innovative therapeutics to im...
Five Prime Therapeutics, Inc. discovers and dev...
At Insmed we are on a mission to transform the lives of patients battling serious ...
At Insmed we are on a mission to transform the ...
Eagle is a specialty pharmaceutical company working to advance safe and efficient ...
Eagle is a specialty pharmaceutical company wor...
Sarepta Therapeutics is a U.S. commercial-stage biopharmaceutical company focused ...
Sarepta Therapeutics is a U.S. commercial-stage...
We have used biochemical, molecular & cell biology and in vivo models to screen, i...
We have used biochemical, molecular & cell biol...
Immunomedics is a clinical-stage biopharmaceutical company developing monoclonal a...
Immunomedics is a clinical-stage biopharmaceuti...
Join the National Investor Network and get the latest information with your interests in mind.